David Okai (@davidokai) header
David Okai (@davidokai) profile picture

Associate Medical Director, The Maudsley - National Specialist Psychiatry Services | Consultant Neuropsychiatrist. Clinical Director - Maudsley Private

London
Joined December 2010
Photo by David Okai (@davidokai)Photo by David Okai (@davidokai)Photo by David Okai (@davidokai)Photo by David Okai (@davidokai)Photo by David Okai (@davidokai)Photo by David Okai (@davidokai)Photo by David Okai (@davidokai)Photo by David Okai (@davidokai)Photo by David Okai (@davidokai)
Pleased with the recent interest in this exciting project below. Our website is now up and running to help clinicians and/or patient volunteers, find out more about the study or enrol. Do please get in touch. 🔬 Exciting Opportunity! We’re recruiting for a MRC funded, groundbreaking ‘brain pacemaker’ study to tackle alcohol and opioid addiction through a randomized control trial (RCT). This study leverages Deep Brain Stimulation (DBS), akin to a heart pacemaker, to normalize brain rhythms. Previous trials have shown significant efficacy. We need: 🔹 Alcohol & Opioid use disorder patients 🔹 Minimum 5-year addiction history with repeated relapses 🔹 Motivated to quit but facing frequent relapses 🔹 May be on methadone/buprenorphine with breakthrough use (greater than 1x/week or 5x/month) Key points: ✔️ DBS is FDA/CE approved for Parkinson’s (since 1997) & OCD (since 2009) ✔️ FDA Breakthrough Device approval for addiction (2022) ✔️ Safe with over 250,000 devices in use globally The device targets the nucleus accumbens and ventral internal capsule fibers, similar to successful OCD treatments. Previous RCTs in this area show good results, with some patients achieving prolonged abstinence after years of struggle. Study design includes physiological mechanism analysis and a clinical RCT, with all participants receiving stimulation in an open-label arm, followed by a crossover trial at six months. Interested? Join us in pioneering this innovative treatment! 🌟 #AddictionResearch #DBS #ClinicalTrials #BrainPacemaker @valvoon For more info please see the website: brain-pacer.com @AlcoholChangeUK @changegrowlive @WeAreWithYou @WeAreWithYou @DDNMagazine @UK_AHA @ActionAddiction @TurningPointUK2 @AlcoholFocus @InstAlcStud
8
1
11
2,251
What an outstanding achievement for a psychiatrist !! See his story in a book review I wrote for his book 2022. Explains Optogenetics - hope helpful!
Congratulations - esp @KarlDeisseroth Only 2nd psychiatrist in history ever to be so awarded. The 1st Wagner Juaregg (an avowed Nazi) got it for malaria therapy for neurosyphillis - best forgotten
50
David Okai retweeted
This has been accepted as likely for many years but nice to see some data confirming it
For clinicians seeing patients with FND 🚨 Fostering diagnostic agreement through neuroscience-informed education/counseling is associated with ⬆️ symptom improvement and return-to-work New article @uoftmedicine with @MollicaAdriano & @DavidLewisPerez dx.doi.org/10.1002/brb3.7149…
1
4
17
3,521
David Okai retweeted
Need mental health support right now? A new 24/7 WhatsApp crisis messaging service is launching across South London. 🫂Free |Confidential | Compassionate Message 0303 330 1511 on WhatsApp.
1
4
7
329
The world of evidence-based Psychiatry should be grateful to @tylerblack32 for engaging with @joannamoncrieff, her challenges and arguments. And, once again, he shows convincingly that her arguments are not supported by the evidence, unless one relies on her selective narratives.
OK @joannamoncrieff ,lets do this. POINT BY POINT 🔽🔽 /2
7
15
1
89
6,580
Can we localise FBDS? (At last ……. After so many years of hypotheses…) . We can get close…. Great work led by @SoontaeLeeMD @SamanthaBanksMD and colleagues
Neuroanatomical localization of faciobrachial dystonic seizures and other ictal phenomena in LGI1 encephalitis revealed at a network-level approach. doi.org/10.1002/epi.70197 #epilepsy #ilae #epilepsiajourn #faciobrachialdystonicseizure #LGI1antibodyencephalitis #MEG #semiology
2
12
35
3,213
Great projects presented at #NNTM. Congratulations to the three finalists, and thank you to everyone who submitted a poster and shared their work with us. #neurotransformation
1
6
270
1/11 🧵 If a clinician works like a chatbot, then chatbots will indeed become better at diagnosis. But some of us do not work like chatbots. Let me share a few scenes from my clinical practice that differ fundamentally from the kind of assessments currently performed by chatbots.
You greatly overvalue the reliability/validity of DSM/ICD diagnoses done by humans. & ignore severe/inherent limitations of the DSM/ICD categorical systems. I've reviewed many thousands of cases with careless/obviously inaccurate diagnoses- & I dont always trust even my own.
2
35
6
133
32,830
Great feedback from the Foundation Course, of the Neurology Academy Masterclass in Sheffield. Not sure what to do about the voice comment after lunch, though!!! 😅@TheNeuroAcademy #parkinson's @rcpsychNeuro #LunchBreak
2
1
5
255
New study!! Suicide risk in primary care, often overlooked in suicide research (which typically focuses on people identified by specialist services). We followed up 1.4M people diagnosed with common mental disorders over 20 years 1/
6
46
2
133
16,395
A great meeting in prospect - neurodevelopment, medico-legal, global, assisted dying and dementia, genes, biomarkers, mania, feotal alcohol... @KarlFristonNews @Mark_Solms @kesleeman @rcpsychNeuro @The_BNPA @CogNPsychiatry @SecretaryINA Please RT
1 month to go until the @rcpsychNeuro conference. Have you booked your place? Join us in-person or online. View the programme and register: bit.ly/42UE #NeuroConf25
2
5
1,514
CTE and normal aging are difficult to distinguish, new study finds news.northwestern.edu/storie… by @NorthwesternU #dementia #TBI #sports #health
9
12
804
Well done @doctorcordelle !!!!👏🏾👏🏾👏🏾🎊
Congratulations Dr Cordelle Ofori! Winner of the #BlackHealthcareAwards Fenton Award 2025. Your outstanding contributions to healthcare excellence and community service make a lasting impact.
1
1
175
We were excited to see Dr. Jacqueline Philips-Owen speak at the House of Commons on behalf of Maudsley Education Consultation service (MECS) sharing how they're supporting students' mental health across South London.
In June, the Maudsley Education Consultation Service joined the Youth Conference at the House of Commons. Dr Jacqueline Philips-Owen shared how we're helping schools across South London support student mental health. Thank you Cllr @ManjuShahul ! @MaudsleyNHS @KingsIoPPN
1
4
15
1,225
David Okai retweeted
Most studies on esketamine (and the UK licence) have been as add-on to antidepressants. This study suggests monotherapy may also be effective - although only short term data. As ever the challenge with (es)ketamine comes in the longer term.
Esketamine nasal spray as a monotherapy improved depressive symptoms in treatment-resistant depression (TRD) compared to placebo. ja.ma/3ZYkZIv
2
8
24
2,778
David Okai retweeted
He et al. recorded neural activity from the motor cortex and thalamus, along with hand tremor signals, in people with essential tremor. Their findings provide new insights into the cortico-thalamic network involved in tremor generation. tinyurl.com/4b3ppah2
11
1
43
6,682
Replying to @ProfRobHoward
Today, at a conference in Pune, India, Dr Sule a senior psychiatrist talked about his 50 years of psychiatry practice in Nashik, India. Only Chlorpromazine and unmodified ECT were available as treatment when he started practice. He expressed gratitude to scientists who made all the progress possible and changed the world for better for all of us and our patients. I think we need to hear more of this to maintain our fortitude and vigour for clinical practice. Otherwise relentless onslaught of anti psychiatry will decimate common sense.
2
5
19
2,442
SUPER COOL…Can a NMDAR-reactive (monovalent) antibody block binding/actions of pathogenic antibodies against the same receptor?? Yes 👍 Many expts in marmosets 🙉 A realistic precision therapeutic? 💊 nature.com/articles/s41467-0… BUT…….if this is to go into patients….🥼🩺
1
3
22
1,080